349 related articles for article (PubMed ID: 20445015)
1. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ; Wilkinson JR
J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
6. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
7. Selegiline and rasagiline: twins or distant cousins?
Knudsen Gerber DS
Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Youdim MB; Gross A; Finberg JP
Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of monoamine oxidase type B and the "cheese effect".
Finberg JP; Gillman K
Int Rev Neurobiol; 2011; 100():169-90. PubMed ID: 21971008
[TBL] [Abstract][Full Text] [Related]
12. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
[TBL] [Abstract][Full Text] [Related]
13. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
White WB; Salzman P; Schwid SR;
Hypertension; 2008 Sep; 52(3):587-93. PubMed ID: 18678789
[TBL] [Abstract][Full Text] [Related]
14. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Youdim MB; Tipton KF
Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419
[TBL] [Abstract][Full Text] [Related]
15. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Meiring L; Petzer JP; Legoabe LJ; Petzer A
Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344
[TBL] [Abstract][Full Text] [Related]
19. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]